Dachaigh › Myeloma iomaill › North Carolina › Durham
Sgrùdaidhean clionaigeach Myeloma iomaill ann an Durham, NC
Tha 37 sgrùdaidhean airson Myeloma iomaill a’ lorg phàirtichean aig làraichean ann agus timcheall air Durham (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
A’ fastadhÌre 3
- Research Site, Chapel Hill · 10 mìle air falbh
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 3
- Durham VAMC, Durham
- University of North Carolina, Chapel Hill · 10 mìle air falbh
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 3
- Duke University Medical Center, Durham
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
A’ fastadhÌre 2
- Duke University Medical Center, Durham
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
A’ fastadhÌre 3
- Durham VAMC, Durham
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
A’ fastadhÌre 2
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mìle air falbh
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
A’ fastadhÌre 2/3
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill · 10 mìle air falbh
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
A’ fastadhÌre 3
- Duke University, Durham
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 2
- University of North Carolina Medical Center, Chapel Hill · 10 mìle air falbh
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
A’ fastadhÌre 1/2
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill · 10 mìle air falbh
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
A’ fastadhÌre 2
- Duke University Health System, Durham
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 1
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mìle air falbh
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
A’ fastadhÌre 1/2
- GSK Investigational Site, Chapel Hill · 10 mìle air falbh
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
A’ fastadhÌre 1
- Duke University Hospital, Durham
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
A’ fastadhÌre 1/2
- Research Site, Durham
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
A’ fastadh
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mìle air falbh
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
A’ fastadhÌre 3
- Research Site, Durham
- Research Site, Chapel Hill · 10 mìle air falbh
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
A’ fastadhÌre 1
- Duke Cancer Center, Durham
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
A’ fastadhÌre 2
- UNC Hospitals Adult Oncology Clinics, Chapel Hill · 10 mìle air falbh
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
A’ fastadhÌre 1/2
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill · 10 mìle air falbh
Selinexor and Backbone Treatments of Multiple Myeloma Patients
A’ fastadhÌre 1/2
- Duke Institute of Cancer/ Duke University, Durham
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 1
- University of North Carolina /ID# 251203, Chapel Hill · 10 mìle air falbh
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
A’ fastadhÌre 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mìle air falbh
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
A’ fastadhÌre 2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mìle air falbh
Registry of Older Patients With Cancer
A’ fastadhSgrùdadh amharc
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mìle air falbh
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
A’ fastadhÌre 3
- Duke University, Durham
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
A’ fastadhÌre 2
- University of North Carolina, Chapel Hill · 10 mìle air falbh
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
A’ fastadhÌre 2
- Duke Comprehensive Cancer Center, Durham
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mìle air falbh
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
A’ fastadhÌre 1
- University of North Carolina Hospitals at Hillsborough, Chapel Hill · 10 mìle air falbh
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
A’ fastadhÌre 1/2
- Duke University Health System (DUHS), Durham
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
A’ fastadhÌre 1
- University Of North Carolina Health Care - Hillsborough Campus /ID# 278230, Hillsborough · 13 mìle air falbh
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
A’ fastadhÌre 1
- University of North Carolina, Chapel Hill · 10 mìle air falbh
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
A’ fastadhÌre 1
- University of North Carolina, Chapel Hill · 10 mìle air falbh
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A’ fastadhÌre 1/2
- Duke University, Durham
- UNC Hospital, Chapel Hill · 10 mìle air falbh
Registry for Adults With Plasma Cell Disorders (PCD's)
A’ fastadhSgrùdadh amharc
- North Carolina Cancer Hospital, Chapel Hill · 10 mìle air falbh
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
A’ fastadhSgrùdadh amharc
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mìle air falbh
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
A’ fastadhÌre 1
- Duke University Health System (DUHS), Durham
Sgrùdaidhean Myeloma iomaill ann am bailtean eile
- New York City, NY60 sgrùdaidhean
- Boston, MA42 sgrùdaidhean
- Atlanta, GA42 sgrùdaidhean
- Houston, TX38 sgrùdaidhean
- Nashville, TN32 sgrùdaidhean
- Denver, CO27 sgrùdaidhean
- Rochester, MN24 sgrùdaidhean
- St. Louis, MO24 sgrùdaidhean
- Columbus, OH24 sgrùdaidhean
- Baldwin Park, CA23 sgrùdaidhean
- Edison, NJ22 sgrùdaidhean
- Chicago, IL22 sgrùdaidhean
Sgrùdaidhean eile ann an Durham
- Aillse a' bhroilleach64 sgrùdaidhean
- Aillse (gach seòrsa)58 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag39 sgrùdaidhean
- Leukemia myeloid geur33 sgrùdaidhean
- Ailse metastatach33 sgrùdaidhean
- Aillse Prostata32 sgrùdaidhean
- Ailseachadh nan Sgamhan32 sgrùdaidhean
- Aillse colorectal28 sgrùdaidhean
- Cancer Ovarian27 sgrùdaidhean
- Leukemia Lymphocytic Cronach27 sgrùdaidhean
- Fàilligeadh a' Chridhe26 sgrùdaidhean
- Cancer Pancreatic24 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.